Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
houre por rosponso.	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kramer Robert</u>						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ]									ck all applic Directo	nship of Reporting Il applicable) Director		10% Ow	ner
(Last) 400 PRC	,	irst) AL DR, SUITE 4	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/10/2015									, y	below)	(give title Corporate Se		Other (specify below) ervices Div	
(Street) GAITHERSBURG MD 20879					- 4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc Line)	Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(City)	(S		(Zip)			- 0-				D:-		£ F		<b>6</b> 1 - 1 - 11-	. 0	1			
1. Title of Security (Instr. 3)  2. Transar Date (Month/Date)			saction	action 2A. D Exec Pay/Year) if any		A. Deemed execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amou Securitie Benefici Owned F	nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A)	or	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock <sup>(1)</sup>			03/1	/10/2015				A		16,514	(2)	A	\$ <mark>0</mark>	74	74,352		D		
Common Stock <sup>(1)</sup>			03/1	0/2015	5			F		2,818	]	)	\$29	71	.,534		D		
Common Stock <sup>(1)</sup> 03/1:				1/2015	2015					422		)	\$28.99	71,112		D			
		-	Гable II -								osed of, convertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	ate, Transacti Code (Ins		ion of		6. Date E. Expiratio (Month/D	n Dat		of Securities		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e   (	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nu of	umber					
Employee Stock Option (right to	\$28.99	03/10/2015			A		33,017		(3)		03/09/2022	Commo Stock	on 33	3,017	\$0	33,017	7	D	

## **Explanation of Responses:**

- 1. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
- 2. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- 3. Vests in three equal installments on March 9, 2016, March 9, 2017 and March 9, 2018.

## Remarks:

/s/ Eric Burt, attorney-in-fact 03/12/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.